This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
Nature Reviews Cardiology Open Access 24 September 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bonaca, M. P. et al. Efficacy and safety of ticagrelor as long-term secondary prevention in patients with peripheral artery disease and prior myocardial infarction. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2016.03.524 (2016)
Bhatt, D. L. et al. Reduction in ischemic events with ticagrelor in diabetic patients: from the PEGASUS-TIMI 54 trial. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2016.03.529 (2016)
Franchi, F. et al. Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 study. JACC Cardiovasc. Interven. http://dx.doi.org/10.1016/j.jcin.2016.02.039 (2016)
Rights and permissions
About this article
Cite this article
Huynh, K. Ticagrelor reduces cardiac events in patients with PAD or diabetes. Nat Rev Cardiol 13, 310–311 (2016). https://doi.org/10.1038/nrcardio.2016.61
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.61